Standort in Gefahr: Absagen für den Investitionsgipfel: Unternehmenschefs kritisieren deutsche Industriepolitik
Die Bundesregierung wirbt mit dem „Invest in Germany“-Gipfel um Vertrauen und Geld internationaler Unternehmen. Doch viele äußern sich kritisch – Pharmachefs sagen sogar ihre Teilnahme ab.
In a matter of days before the critical investors' event organized by the German government in Berlin, the mood in certain sectors is not favorable. Several key energy laws have been pending for months, causing uncertainty among business owners. Additionally, healthcare sector cost-cutting initiatives are generating frustration.
Chancellor Friedrich Merz and his cabinet aim to convey that investments are welcome and Germany is an attractive location for such endeavors. To this end, they have invited domestic and international company executives to a summit titled "Invest in Germany" on Monday and Tuesday, providing them with an opportunity for one-on-one discussions with the Chancellor and ministers.
The timing is generally advantageous. Yves Meyer-Bülow, a partner at the infrastructure investor I Squared, notes, "Germany has the historic opportunity to reinvent its infrastructure as a competitive advantage. After two decades of insufficient public investments, there is a significant catch-up need." Roman Waleczek, managing director of the financial services firm Rothschild, adds, "Germany's industrial location offers significant investment opportunities, particularly in scaling and modernizing the economy. The 'Invest in Germany Summit' sends an important signal in this regard."
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
